| PEB0241 | Virological efficacy and tolerability of dual therapy maintenance with dolutegravir plus lamivudine in heavily treatment experienced HIV-infected patients: Four years data from DOLULAM study | E-poster | B32 |
| PEB0296 | Virological characterization in newly HIV diagnosed adolescents in Spain during 1980-2017 | E-poster | B51 |
| OAA0106 | Virological and immunological evaluation of individuals with spontaneous persistent viral control without ART | Oral abstract session with live Q&A | A4 |
| PEB0112 | Virologic outcomes among patients on first-line antiretroviral therapy (ART) following transition to dolutegravir in a tertiary HIV clinic in Uganda | E-poster | B5 |
| PEE1628 | Viral suppression in 'stable HIV+ patients in two community models of ART delivery: A cluster-randomized trial nested within the HPTN 071 (PopART) trial in Lusaka, Zambia | E-poster | E42 |
| PEB0278 | Viral suppression by delivery and birth outcomes among pregnant women living with HIV using dolutegravir in the United States: A comparative effectiveness and safety analysis | Poster Exhibition | B44 |
| PEC0394 | Viral suppression and contraceptive use among women initiating dolutegravir-containing antiretroviral therapy in Kenya: The Chaguo Langu study | E-poster | C7 |
| PED1124 | Viral suppression and barriers to medical care engagement in a national probability sample of HIV-positive young black men who have sex with men | E-poster | D39 |
| PEC0704 | Viral load testing coverage among pregnant women in PEPFAR-supported countries, October 2018 ' September 2019 | E-poster | C42 |
| PEC0520 | Viral load suppression and recency of infection among HIV-positive sexually transmitted infection (STI) service attendees | E-poster | C26 |